Rola aripiprazolu w leczeniu schizofrenii oraz zaburzeń nastroju

• Authors: Aleksandra Gorostowicz , Marcin Siwek

Title variants

EN

The role of aripiprazole in the treatment of schizophrenia and mood disorders

• Languages of publication: PL

Abstracts

PL

Aripiprazole belongs to atypical antipsychotic medication of the so-called third generation, with a mechanism of action different from most antipsychotic drugs available. Its receptor action profile contributes to relatively good tolerance and low risk of metabolic complications. The high level of safety of aripiprazole was described in multiple groups of patients – the elderly and patients suffering from diabetes as well as kidney, liver and heart diseases. Furthermore, an increasing number of studies show that the drug used in the population of pregnant women was not linked to a clinically significant risk of major birth defects. At present, aripiprazole is mainly used in the treatment of schizophrenia, bipolar disorder and recurrent treatment-resistant depression and occupies a significant position in the recommendations for the treatment regimens for these diseases. In persons with mental illness, somatic diseases frequently coexist (among them, the metabolic syndrome and diabetes) and the inclusion of aripiprazole therapy may result in an additional improvement in metabolic parameters. The literature data suggest that polytherapy with the use of aripiprazole (especially in combination with such atypical drugs as olanzapine, clozapine or risperidone) can bring tangible benefits for patients with schizophrenia. Its clinical utility is significant in the context of the difficulties encountered in the treatment of schizophrenia and bipolar disorder – the lack of cooperation on the part of the patients with respect to drug consumption and the coexistence of numerous somatic ailments in both diseases.

EN

Aripiprazol jest atypowym lekiem przeciwpsychotycznym tzw. trzeciej generacji, o odmiennym mechanizmie działania od większości dostępnych leków przeciwpsychotycznych. Jego profil działania receptorowego przyczynia się do względnie dobrej tolerancji oraz niskiego ryzyka powikłań metabolicznych. Opisano wysokie bezpieczeństwo stosowania aripiprazolu w wielu grupach chorych – u osób starszych, u pacjentów z cukrzycą, chorobami nerek, wątroby, serca, ponadto coraz więcej badań wskazuje, iż lek stosowany w populacji kobiet w ciąży nie wiązał się z istotnym klinicznie wzrostem ryzyka powstawania dużych wad wrodzonych u płodów. Obecnie aripiprazol jest stosowany głównie w leczeniu schizofrenii, choroby afektywnej dwubiegunowej oraz lekoopornej depresji nawracającej i zajmuje znaczącą pozycję w rekomendacjach dotyczących schematów leczenia tych schorzeń. U osób z chorobami psychicznymi często współwystępują choroby somatyczne (w tym zespół metaboliczny oraz cukrzyca) i uwzględnienie aripiprazolu w terapii może wiązać się z dodatkową poprawą parametrów metabolicznych. Z danych literaturowych wynika, że politerapia z użyciem aripiprazolu (szczególnie w połączeniu z takimi lekami atypowymi, jak olanzapina, klozapina czy risperidon) może nieść wymierne korzyści dla pacjentów ze schizofrenią. Jego przydatność kliniczna jest znacząca w kontekście napotykanych trudności w terapii schizofrenii i choroby dwubiegunowej – braku współpracy pacjentów w zakresie zażywania leków oraz współwystępowania licznych schorzeń somatycznych w obu tych chorobach.

Keywords

EN

aripiprazol; choroba dwubiegunowa; depresja; leczenie; schizofrenia

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Psychiatria i Psychologia Kliniczna
• Year: 2018
• Volume: 18
• Issue: 3
• Pages: 296–305

Contributors

author

Aleksandra Gorostowicz

• Katedra Psychiatrii, Uniwersytet Jagielloński, Collegium Medicum, Kraków, Polska

author

Marcin Siwek

• Zakład Zaburzeń Afektywnych, Katedra Psychiatrii, Uniwersytet Jagielloński, Collegium Medicum, Kraków, Polska

References

• Bak M, Fransen A, Janssen J et al.: Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014; 9: e94112.
• Barak Y, Aizenberg D: Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia. J Obes 2011; 2011. pii: 898013.
• Bazire S: Psychotropic Drug Directory 2018. Lloyd-Reinhold Publications, London 2018.
• Bellet F, Beyens MN, Bernard N et al.: Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. Pharmacoepidemiol Drug Saf 2015; 24: 368–380.
• Briles JJ, Rosenberg DR, Brooks BA et al.: Review of the safety of second-generation antipsychotics: are they really “atypically” safe for youth and adults? Prim Care Companion CNS Disord 2012; 14. pii: PCC.11r01298.
• Carpenter WT, Buchanan RW: Lessons to take home from CATIE. Psychiatr Serv 2008; 59: 523–525.
• Chakrabarti S: Treatment-adherence in bipolar disorder: a patientcentred approach. World J Psychiatry 2016; 6: 399–409.
• Chang JS, Ahn YM, Park HJ et al.: Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69: 720–731.
• Chen JX, Su YA, Bian QT et al.: Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015; 58: 130–140.
• Chung AK, Chua SE: Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol 2011; 25: 646–666.
• Conley RR, Kelly DL: Drug-drug interactions associated with secondgeneration antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 2007; 40: 77–97.
• Cuomo A, Goracci A, Fagiolini A: Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. J Affect Disord 2018; 228: 229–237.
• Damkier P, Videbech P: The safety of second-generation antipsychotics during pregnancy: a clinically focused review. CNS Drugs 2018; 32: 351–366.
• Dibonaventura M, Gabriel S, Dupclay L et al.: A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012; 12: 20.
• Di Sciascio G, Riva MA: Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat 2015; 11: 2635–2647.
• Fajutrao L, Locklear J, Priaulx J et al.: A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health 2009; 5: 3.
• Fleischhacker WW, Heikkinen ME, Olié JP et al.: Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13: 1115–1125.
• Fleischhacker WW, Sanchez R, Perry PP et al.: Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, noninferiority study. Br J Psychiatry 2014; 205: 135–144.
• Forty L, Ulanova A, Jones L et al.: Comorbid medical illness in bipolar disorder. Br J Psychiatry 2014; 205: 465–472.
• Gallego JA, Nielsen J, De Hert M et al.: Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012; 11: 527–542.
• Galling B, Roldán A, Hagi K et al.: Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16: 77–89.
• Galling B, Roldán A, Rietschel L et al.: Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf 2016; 15: 591–612.
• García S, Martínez-Cengotitabengoa M, López-Zurbano S et al.: Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 2016; 36: 355–371.
• Geddes JR, Miklowitz DJ: Treatment of bipolar disorder. Lancet 2013; 381: 1672–1682. Gitlin M, Frye MA: Maintenance therapies in bipolar disorders. Bipolar Disord 2012; 14 Suppl 2: 51–65.
• Goodwin GM, Haddad PM, Ferrier IN et al.: Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30: 495–553.
• Greenaway M, Elbe D: Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2009; 18: 250–260.
• Han C, Wang SM, Lee SJ et al.: Optimizing the use of aripiprazole augmentation in the treatment of major depressive disorder: from clinical trials to clinical practice. Chonnam Med J 2015; 51: 66–80.
• Hassan M, Lage MJ: Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009; 66: 358–365.
• Henderson DC, Fan X, Copeland PM et al.: Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009; 29: 165–169.
• Higashi K, Medic G, Littlewood KJ et al.: Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 2013; 3: 200–218.
• Janicak PG, Glick ID, Marder SR et al.: The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry 2009; 70: 25–35.
• Jarema M (ed.): Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. 2nd ed., Via Medica, Gdańsk 2015.
• Jiang XJ, Wu FX, Zhang JP et al.: Effects of risperidone and aripiprazole on serum levels of prolactin, testosterone and estradiol in female patients with schizophrenia. Drug Res (Stuttg) 2018. DOI: 10.1055/s-0044-102093.
• Kahn RS, Giannopoulou A: The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert Rev Neurother 2015; 15: 969–981.
• Kane JM, Correll CU, Goff DC et al.: A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009; 70: 1348–1357.
• Kane JM, Leucht S, Carpenter D et al.; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders: The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64 Suppl 12: 5–19.
• Kessing LV, Thomsen AF, Mogensen UB et al.: Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010; 197: 266–271.
• Kirino E: Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Ann Gen Psychiatry 2017; 16: 43.
• Komossa K, Rummel-Kluge C, Schmid F et al.: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; (4): CD006569.
• Lambert M, Karow A, Leucht S et al.: Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci 2010; 12: 393–407.
• Leucht S, Samara M, Heres S et al.: Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 2016; 42 Suppl 1: S90–S94.
• Leucht S, Samara M, Heres S et al.: Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 2015; 41: 1397–1402.
• Leucht S, Samara M, Heres S et al.: Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 2014; 40: 314–326.
• Lew KH, Chang EY, Rajagopalan K et al.: The effect of medication adherence on health care utilization in bipolar disorder. Manag Care Interface 2006; 19: 41–46.
• Li DJ, Tseng PT, Stubbs B et al.: Efficacy, safety and tolerability of aripiprazole in bipolar disorder: an updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry 2017; 79: 289–301.
• Lieberman JA: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 2007; 68: e04.
• Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223.
• Lindström L, Lindström E, Nilsson M et al.: Maintenance therapy with second generation antipsychotics for bipolar disorder – a systematic review and meta-analysis. J Affect Disord 2017; 213: 138–150.
• Mago R, Borra D, Mahajan R: Role of adverse effects in medication nonadherence in bipolar disorder. Harv Rev Psychiatry 2014; 22: 363–366.
• Mailman RB, Murthy V: Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010; 16: 488–501.
• Mallikaarjun S, Shoaf SE, Boulton DW et al.: Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet 2008; 47: 533–542.
• Marder SR, West B, Lau GS et al.: Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry 2007; 68: 662–668.
• Martinez-Aran A, Scott J, Colom F et al.: Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry 2009; 70: 1017–1023.
• Mauri MC, Paletta S, Maffini M et al.: Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 2014; 13: 1163–1191.
• McEvoy JP, Daniel DG, Carson WH Jr et al.: A randomized, doubleblind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007; 41: 895–905.
• McIntyre RS, Soczynska JK, Woldeyohannes HO et al.: Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother 2007; 8: 1001–1009.
• Miller C, Bauer MS: Excess mortality in bipolar disorders. Curr Psychiatry Rep 2014; 16: 499.
• Mizuno Y, Suzuki T, Nakagawa A et al.: Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and metaanalysis. Schizophr Bull 2014; 40: 1385–1403.
• Morden NE, Lai Z, Goodrich DE et al.: Eight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia. Gen Hosp Psychiatry 2012; 34: 368–379.
• Pae CU: A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf 2009; 8: 373–386.
• Pae CU, Wang SM, Han C et al.: Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Int Clin Psychopharmacol 2017; 32: 235–248.
• Patel KR, Cherian J, Gohil K et al.: Schizophrenia: overview and treatment options. P T 2014; 39: 638–645.
• Peters-Strickland T, Zhao C, Perry PP et al.: Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectr 2016; 21: 460–465.
• Potkin SG, Preda A: Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert Opin Pharmacother 2016; 17: 395–407.
• Rado J, Janicak PG: Aripiprazole for late-life schizophrenia. Clin Interv Aging 2010; 5: 253–258.
• Rapid Response Report: Summary with Critical Appraisal: Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON); 2016 May 25.
• Reininghaus U, Dutta R, Dazzan P et al.: Mortality in schizophrenia and other psychoses: a 10-year follow-up of the ӔSOP first-episode cohort. Schizophr Bull 2015; 41: 664–673.
• Romeo B, Blecha L, Locatelli K et al.: Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: efficacy and safety. J Psychopharmacol 2018; 32: 385–396.
• Sahraian A, Ehsaei Z, Mowla A: Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2018; 84: 267–271.
• Sajatovic M, Coconcea N, Ignacio RV et al.: Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry 2008; 69: 41–46.
• Srisurapanont M, Suttajit S, Maneeton N et al.: Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res 2015; 62: 38–47.
• Stroup TS, Byerly MJ, Nasrallah HA et al.: Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 2013; 146: 190–195.
• Sun SX, Liu GG, Christensen DB et al.: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007; 23: 2305–2312.
• Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64: 1715–1736.
• Taipale H, Mittendorfer-Rutz E, Alexanderson K et al.: Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res 2017. pii: S0920-9964(17)30762-4.
• Velligan DI, Weiden PJ, Sajatovic M et al.; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70 Suppl 4: 1–46; quiz 47–48.
• Wani RA, Dar MA, Chandel RK et al.: Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatr Dis Treat 2015; 11: 685–693.
• Weiden PJ, Mackell JA, McDonnell DD: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51–57.
• Woo YS, Bahk WM, Park YM et al.: Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder. Int Clin Psychopharmacol 2016; 31: 275–286.
• Wu CS, Wang SC, Yeh IJ et al.: Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. J Clin Psychiatry 2016; 77: e573–e579.
• Yatham LN, Kennedy SH, Parikh SV et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20: 97–170.

• Document Type: article